Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2023
Details:
LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
LUM-201, an oral growth hormone secretagogue, has a unique mechanism of action, targeting specific receptors on the pituitary and hypothalamus to stimulate the natural pulsatile secretion of growth hormone for moderate idiopathic PGHD patients.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
LUM-201, an oral growth hormone stimulating small molecule demonstrate a favorable safety profile as data from both OraGrowtH trials to date show comparable safety and tolerability to the rhGH subjects in the trials.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion of Growth Hormone from the pituitary gland. This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD.
Lead Product(s): Ibutamoren
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Massachusetts General Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
Lumos Pharma intends to analyze these interim datasets separately and also perform a combined analysis to increase the number of subjects in the top two LUM-201 dose cohorts.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
The subgroup of the Merck 020 trial specifically examined the effect LUM-201 had on the pulsatile secretion of growth hormone (GH) over 24 hours in patients with PGHD after 6 months of treatment with LUM-201, compared to that patient’s baseline GH secretion.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
Poster 7102 presents an analysis of data from a prior clinical study comparing the peak growth hormone (GH) response of LUM-201 to that of standard GH secretagogues in children naïve-to-treatment, previously diagnosed with growth hormone deficiency (GHD).
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2021
Details:
The Merck 020 study was a placebo-controlled trial of LUM-201 and recombinant human growth hormone (rhGH) in which all randomized subjects had pretreatment testing, including IGF-1 and peak GH levels determined after a single dose of LUM-201.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
The trial will evaluate three dose levels of LUM-201 in PGHD patients against a comparator arm of standard-of-care injectable growth hormone therapy.
Lead Product(s): Ibutamoren
Therapeutic Area: Endocrinology Product Name: LUM-201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020